Opiant Pharmaceuticals Stock Forecast, Price & News

Opiant Pharmaceuticals' stock was trading at $10.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OPNT shares have decreased by 37.7% and is now trading at $6.76.
View which stocks have been most impacted by COVID-19.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Opiant Pharmaceuticals.

Opiant Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Opiant Pharmaceuticals.

Opiant Pharmaceuticals will be holding an earnings conference call on Thursday, November 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) announced its quarterly earnings data on Thursday, August, 6th. The technology company reported ($0.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.31) by $0.26. The technology company earned $6.31 million during the quarter, compared to analyst estimates of $6.47 million. Opiant Pharmaceuticals had a net margin of 25.32% and a negative return on equity of 2.43%.
View Opiant Pharmaceuticals' earnings history.

1 equities research analysts have issued 1 year target prices for Opiant Pharmaceuticals' stock. Their forecasts range from $42.00 to $42.00. On average, they anticipate Opiant Pharmaceuticals' stock price to reach $42.00 in the next twelve months. This suggests a possible upside of 521.3% from the stock's current price.
View analysts' price targets for Opiant Pharmaceuticals.

Opiant Pharmaceuticals saw a decrease in short interest in October. As of October 15th, there was short interest totaling 5,900 shares, a decrease of 24.4% from the September 30th total of 7,800 shares. Based on an average trading volume of 22,300 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.2% of the shares of the company are sold short.
View Opiant Pharmaceuticals' Short Interest.

Some companies that are related to Opiant Pharmaceuticals include Almaden Minerals (AAU), Almaden Minerals (AAU), Fission Uranium (FCUUF), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Amerigo Resources (ARREF), Mountain Province Diamonds (MPVDF), Westwater Resources (WWR), Paramount Gold Nevada (PZG), Paramount Gold Nevada (PZG), Bullfrog Gold (BFGC), Atlatsa Resources (ATLRF), US Gold (USAU), Dakota Territory Resource (DTRC) and Santa Fe Gold (SFEG).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include Cara Therapeutics (CARA), AcelRx Pharmaceuticals (ACRX), Sangamo Therapeutics (SGMO), Synchrony Financial (SYF), Vodafone Group (VOD), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP) and CyberArk Software (CYBR).

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

Opiant Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Marquette Asset Management LLC (0.19%). Company insiders that own Opiant Pharmaceuticals stock include Ann L Macdougall, David D O'toole, Gabrielle Alison Silver, Michael Sinclair, Phil Skolnick, Roger Crystal and Thomas T Thomas.
View institutional ownership trends for Opiant Pharmaceuticals.

OPNT stock was purchased by a variety of institutional investors in the last quarter, including Marquette Asset Management LLC. Company insiders that have bought Opiant Pharmaceuticals stock in the last two years include Ann L Macdougall, David D O'toole, Gabrielle Alison Silver, and Thomas T Thomas.
View insider buying and selling activity for Opiant Pharmaceuticals.

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OPNT stock can currently be purchased for approximately $6.76.

Opiant Pharmaceuticals has a market capitalization of $28.78 million and generates $40.52 million in revenue each year. The technology company earns $11.59 million in net income (profit) each year or $0.20 on an earnings per share basis. Opiant Pharmaceuticals employs 21 workers across the globe.

The official website for Opiant Pharmaceuticals is www.opiant.com.

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]